- Company
- JW Pharm Hemlibra's sales tops KRW 10 bil for the 1st time
- by Chon, Seung-Hyun Dec 7, 2023 05:47am
- Annual sales of JW Pharmaceutical's Hemlibra has surpassed the 10 billion won mark for the first time since its launch in Korea. The expanded reimbursement significantly boosted sales, by threefold. According to the pharmaceutical research agency IQVIA, Hemlibra's Q3 sales reached 6.8 billion won, a 261.3% increase from 1.9 billion won in th
- Company
- Bemarituzumab is granted ODD status in Korea
- by Eo, Yun-Ho Dec 7, 2023 05:47am
- The new gastric cancer drug bemarituzumab received an orphan drug status in Korea. The Ministry of Food and Drug Safety (MFDS) recently announced so through the orphan drug designation notice. Specifically, the drug is indicated to treat patients with fibroblast growth factor receptor 2b (FGFR2b) overexpression and unresectable locally advan
- Company
- Dong-A and Pfizer win Industry Ad-PR Awards
- by Kim, Jin-Gu Dec 7, 2023 05:47am
- Dong-A Pharmaceutical's ‘Bacchus’ and Pfizer Korea's 'Green Move Campaign' won the grand award in the advertising and PR categories of the 2023 Korea Pharmaceutical and Bio-Industry Advertising and PR Awards. On the 6th, Dailypharm (CEO: Jeong Seok Lee) held the ‘2023 Korea Pharmaceutical and Bio-Industry Advertising and PR Awards Ceremony
- Company
- Jemperli becomes 1st immunotherapy for endometrial cancer
- by Eo, Yun-Ho Dec 6, 2023 06:00am
- The first reimbursed immunotherapy option has been introduced to the field of endometrial cancer in Korea. According to industry sources, GSK Korea’s PD-1 inhibitor Jemperli (dostarlimab) has been listed for reimbursement in Korea from December 1st. Since receiving marketing authorization from the Ministry of Food and Drug Safety in D
- Company
- Erleada chases leader Xtandi in prostate cancer mkt
- by Kim, Jin-Gu Dec 6, 2023 06:00am
- Astellas Pharm Korea ‘Xtandi (enzalutamide)’ took the lead among oral androgen receptor targeted agents (ARTAs) used to treat prostate cancer. In comparison to declining sales of Janssen's ‘Zytiga (Abiraterone),’ sales of Janssen's other prostate cancer drug ‘Erleada (Apalutamide)’ has been rapidly increasing since being released ju
- Company
- AbbVie Korea strengthens its autoimmune disease pipeline
- by Eo, Yun-Ho Dec 5, 2023 05:48am
- AbbVie Korea is actively working to advance its position in the field of autoimmune diseases. According to industry sources, AbbVie Korea successfully expanded the indications for its Interleukin-23(IL-23) inhibitor 'SKYRIZI (Risankizumab)’ and JAK inhibitor ‘RINVOQ (Upadacitinib).’ On November 15th, an indication was added for SKY
- Company
- Companies in KOR and abroad compete in Eylea biosimilar mkt
- by Son, Hyung-Min Dec 5, 2023 05:48am
- Intense challenges are being made against Bayer's Eylea, the current leader in the macular degeneration market. Not only domestic biosimilar companies like Celltrion and Samsung Bioepis but also traditional pharmaceutical companies such as Sam Chun Dang Pharm have thrown down the gauntlet. Bayer and Regeneron, the original developers of
- Company
- Celltrion applies for US approval of its Prolia biosimilar
- by Chon, Seung-Hyun Dec 4, 2023 05:13am
- Celltrion announced today that it has filed an application for the marketing authorization of its, ‘CT-P41,’ to the US Food and Drug Administration (FDA). CT-P41 is a biosimilar of ‘Prolia,’ a treatment for osteoporosis. Based on the results of a global Phase III clinical trial on CT-P41, Celltrion filed for marketing authorization of
- Company
- Pharma companies fiercely compete to develop ADC drugs
- by Son, Hyung-Min Dec 1, 2023 05:35am
- Competition among domestic pharmaceutical companies to secure new antibody-drug conjugate (ADC) technology has been intensifying in Korea. With ADC drugs recently demonstrating an effect on various cancer types, there is an analysis that the industry is making active measures to secure new ADC technologies. According to the pharmaceutical
- Company
- AstraZeneca appoints Sewhan Chon as new Country President
- by Eo, Yun-Ho Dec 1, 2023 05:35am
- Sewhan Chon (49), former Country President of AstraZeneca Indonesia, has been appointed the new Country President of AstraZeneca Korea. According to industry sources, Sewhan Chon has officially taken office as the Country President of AstraZeneca Korea as of the 1st. With the appointment, the former Country President, Kim Sang-pyo (53),
